March 2019 Question of the Month

How will the HHS proposed rule changes to Medicare Part D and Medicaid drug rebate safe harbors impact pharmaceutical product net costs for PBMs?

Higher net costs after the implementation of the proposed rule: 50%

Lower net costs after the implementation of the proposed rule: 12.5%

No impact, net costs will be at the same levels as today: 37.5%